Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-40786
Borsig, L (2010). Heparin as an inhibitor of cancer progression. Progress in Molecular Biology and Translational Science, 93:335-349.
View at publisher
Heparin is frequently used for treatment of cancer-associated thromboembolism. Accumulating clinical evidence indicates that cancer patients treated with unfractionated and low-molecular weight heparin survives longer that patients treated by other anticoagulants, especially patients in the early stage of a disease. Experimental analysis from a number of animal models constantly provides evidence about the ability of heparin to attenuate metastasis. The non-anticoagulant activity of heparin on metastasis includes the ability to inhibit cell-cell-interaction through blocking of P- and L-selectin, to inhibit extracellular matrix protease-heparanase, and to inhibit angiogenesis. This chapter summarizes the current experimental evidence on the biology of heparin during cancer progression with the focus on potential mechanism of heparin antimetastatic activity.
70 downloads since deposited on 21 Jan 2011
5 downloads since 12 months
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > Institute of Physiology
07 Faculty of Science > Institute of Physiology
|Dewey Decimal Classification:||570 Life sciences; biology|
|Date:||21 September 2010|
|Deposited On:||21 Jan 2011 11:07|
|Last Modified:||05 Apr 2016 14:30|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page